breast cancer, controlled ovarian stimulation, estradiol, tamoxifen, letrozole. borstkanker, ovariele stimulatie, oestradiol, tamoxifen, letrozol.
Conditions
Interventions
Group 1 will receive tamoxifen (60 mg per day, orally) in addition to COS. Group 2 will receive letrozoel (5 mg per day, orally) in addition to COS. Group 3 will undergo standard COS with no additiona
Sponsors
Academical Medical Center
Eligibility
Inclusion criteria
Inclusion criteria: - Age 18 – 43 years - Confirmed breast cancer (ER+, ER- or unknown ER status) - Candidate for oocyte or embryocryopreservation (as approved by referring breast cancer specialist and the centre for reproductive medicine that the women is referred to) - Willing and able to give informed consent
Exclusion criteria
Exclusion criteria: - Contraindication to study medication - Use of medication that opposes effect of study medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome is number of oocytes retrieved at follicle apsiration. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Number of mature oocytes retrieved - Number of oocytes or embryos banked - Peak E2 levels during COS defined as serum E2 level measured on the day of ovulation trigger | — |
Contacts
Public ContactM. Goddijn
Academic medical centre, location Q3-120 Postbus 22660
Outcome results
None listed